Lee's Pharmaceutical Co., Ltd. (0950.HK) Quarterly Report Review: Revenue Growth Speeds Up, R&D News Spreads Frequent
國信證券Dec 3, 2018 00:00
Comments on the quarterly report of Li's Big Pharmaceutical Company (0950.HK): the sales of existing products are accelerated and actively promoted in the research and development pipeline.
光大證券May 28, 2018 00:00
Comments on 0950.HK Annual report: core products get out of the sales bottleneck and continue to increase investment in research and development
國信證券Mar 27, 2018 00:00
Lee's Pharmaceuticals (00950.HK): Entering the R&D Harvest Period, Definitive Growth Expectations Continue to Increase
國信證券Feb 13, 2018 00:00
Lee's Pharmaceutical Company (950.HK): Model adjusted based on first-half results; new target price of HK$8.00
匯富金融Sep 9, 2016 00:00
Comments on the Annual report of Li's Big Pharmaceutical Company (950.HK): the reserve products are rich and the new target price is HK $10.00 for future growth.
匯富金融Apr 5, 2016 00:00
Lee's Pharmaceutical Company (950.HK) Research Briefing: Maintaining a Growth Rate of Over 25% for Seven Consecutive Years
國元(香港)Mar 21, 2014 00:00
Morgan Stanley first "increased its holdings" to Li's Big Pharmaceutical Co. (00950-HK), with the driving force of coordinated growth.
摩根士丹利Feb 7, 2011 15:24
No Data
No Data